Bayer AG (FRA:BAYN) has been assigned a consensus rating of “Hold” from the twenty-four research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is €80.57 ($93.68).
A number of equities analysts have issued reports on the company. Warburg Research set a €61.00 ($70.93) price objective on Bayer and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Credit Suisse Group set a €70.00 ($81.40) price objective on Bayer and gave the stock a “buy” rating in a report on Wednesday, July 31st. Kepler Capital Markets set a €70.00 ($81.40) price objective on Bayer and gave the stock a “neutral” rating in a report on Thursday, June 27th. Barclays set a €85.00 ($98.84) price objective on Bayer and gave the stock a “buy” rating in a report on Tuesday, July 30th. Finally, Nord/LB set a €56.00 ($65.12) price objective on Bayer and gave the stock a “neutral” rating in a report on Tuesday, July 30th.
Shares of Bayer stock traded down €1.04 ($1.21) during midday trading on Wednesday, reaching €63.92 ($74.33). 3,384,068 shares of the company’s stock traded hands. The company’s 50 day moving average is €59.09. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: Quick Ratio
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.